Acta Scientific Medical Sciences (ASMS)(ISSN: 2582-0931)

Research Article Volume 5 Issue 11

Studying the Pathogenesis of Retinopathy of Prematurity - From Theory to Practice

Katargina LA, Chesnokova NB, Balatskaya NV, Beznos OV, Pavlenko TA, Osipova NA* and Panova AYu

Helmholtz National Medical Research Center of Eye Diseases, Moscow, Russia

*Corresponding Author: Osipova NA, Helmholtz National Medical Research Center of Eye Diseases, Moscow, Russia.

Received: September 11, 2021; Published:



The study of the pathogenesis of retinopathy of prematurity (ROP) is the basis for solving clinical problems designed to reduce the level of visual impairment due to ROP.

Purpose: the search for new molecular participants in the development of ROP to build a pathogenetically sustainable basis for improving screening, monitoring, prevention and treatment of the disease.

Material and methods: a comprehensive clinical and experimental study was carried out (763 premature infants of the risk group for ROP were examined in the clinic and 145 Wistar rat pups were included in the experiment), including an assessment of the local and systemic level of 49 cytokines of various biological effects, 4 monoamines and angiotensin-II (AT-II) at different stages of the development of the pathological process.

Results: 8 potential laboratory markers of development and unfavorable course of ROP were identified: content of MCP1 > 95 pg/ml, IGF-II > 140 pg/ml, TGF-β1 < 18000 pg/ml and IGF-I < 24 pg/mg in blood serum in premature infants before the first signs of the disease and content of VEGF-A > 108 pg/ml, TGFβ2 > 100 pg/ml, PDGF-BB > 1800 pg/ml, the serotonin < 17.0 pg/ml in blood serum in premature infants with ROP manifestation. L-DOPA and AT-II indicated its prognostic function in the experiment. All of the listed molecular agents can also be considered as targets for the development of new drugs serving for the prevention and treatment of ROP.

Conclusion: a pathogenetically substantiated basis is build for the development of new drug treatments and prevention of ROP, as well as outline ways to improve the ROP screening system.

Keywords: Retinopathy of Prematurity; Pathogenesis; Screening; Prevention; Treatment



  1. Cao JH., et al. “Colorado Retinopathy of Prematurity model: a multi-institutional validation study”. Journal of AAPOS3 (2016): 220-225.
  2. Biniwale M., et al. “Early postnatal weight gain as a predictor for the development of retinopathy of prematurity”. Journal of Maternal-Fetal and Neonatal Medicine 3 (2019): 429-433.
  3. Pivodic A., et al. “Individual Risk Prediction for Sight-Threatening Retinopathy of Prematurity Using Birth Characteristics”. JAMA Ophthalmology1 (2019): 1-9.
  4. Kim SJ., et al. “Identification of candidate genes and pathways in retinopathy of prematurity by whole exome sequencing of preterm infants enriched in phenotypic extremes”. Scientific Report 11 (2021): 4966.
  5. Katargina LA., et al. “The role of the systemic disbalance of serum cytokine levels in pathogenesis of retinopathy of prematurity”. Rossijskaya Pediatricheskaya Ophthlmologija 4 (2015): 16-20.
  6. Chen J., et al. “Retinopathy of prematurity”. Angiogenesis 2 (2007): 133-140.
  7. Hartnett ME. “Studies on the Pathogenesis of Avascular Retina and Neovasculatization into the Vitreous in Peripheral Severe Retinopathy of Prematurity (An American Ophthalmological Society Thesis)”. Transactions of the American Ophthalmological Society 108 (2010): 96-119.
  8. Panova AYu. “The role of the factors of pathological angiogenesis in pathogenesis of retinopathy of prematurity”. Clinico-experimental study: autoreferat dissertacii kandidata medicinskikh nauk. - Moskow (2021): 21.
  9. Katargina LA., et al. “The role of catecholamines in the development of pathological retina neovascularization in an experimental model of retinopathy of prematurity in rats”. Doklady Akademii nauk3 (2019): 313-317.
  10. Katargina LA., et al. “Studying the pathogenic role of catecholamines in the development of retinopathy of prematurity on an experimental model of the disease”. Russian Ophthalmological Journal4 (2019): 64-69.
  11. Katargina LA., et al. “Angiogenic properties of catecholamines from the viewpoint of the pathogenesis of retinopathy of prematurity”. Russian Ophthalmological Journal4 (2018): 49-54.
  12. Katargina LA., et al. “The role of monoamines in the regulation of angiogenesis and the prospects for their use in treatment of retinopathy of prematurity”. Rossijskaya Pediatricheskaya Ophthlmologija2 (2018): 76-80.
  13. Katargina LA., et al. “Angiotensin-II as a trigger factor in the development of retinopathy of prematurity”. Oftal’mologija4 (2020): 746-751.
  14. Katargina LA., et al. “Prognostic value estimation of monoamins systemic level in retinopathy of prematurity in experiment”. Sovremennye Tehnologii v Medicine 3 (2021): 41-46.
  15. Federal clinical guidelines (National protocol). "Diagnostics, monitoring and treatment of the active phase of retinopathy of prematurity”. Rossijskaya Pediatricheskaya Ophthlmologija 1 (2015): 54-60.
  16. Katargina LA., et al. “Pathomorphological features of the development of experimental retinopathy of prematurity”. Mezhdunarodnyj zhurnal prikladnyh i fundamental'nyh issledovanii2 (2017): 190-194.
  17. Zheng Y., et al. “Novel peptide derived from IGF-2 displays anti-angiogenic activity in vitro and inhibits retinal angiogenesis in a model of oxygen-induced retinopathy”. Clinical and Experimental Ophthalmology 9 (2020): 1261-1275.
  18. Eastlake K., et al. “Müller glia as an important source of cytokines and inflammatory factors present in the gliotic retina during proliferative vitreoretinopathy”. Glia4 (2016): 495-506.
  19. Yu H., et al. “Serum concentrations of cytokines in infants with retinopathy of prematurity”. APMIS9 (2014): 818-823.
  20. Natarajan G., et al. “Circulating β chemokine and MMP 9 as markers of oxidative injury in extremely low birth weight infants”. Pediatric Research1 (2010): 77-82.
  21. Yoshida S., et al. “Role of MCP‐1 and MIP‐1α in retinal neovascularization during postischemic inflammation in a mouse model of retinal neovascularization”. Journal of Leukocyte Biology1 (2003): 137-144.
  22. Yoshida S., et al. “Induction of IL-8, MCP-1, and bFGF by TNF-α in retinal glial cells: implications for retinal neovascularization during post-ischemic inflammation”. Graefe's Archive for Clinical and Experimental Ophthalmology 5 (2004): 409-413.
  23. Hong KH., et al. “Monocyte chemoattractant protein-1-induced angiogenesis is mediated by vascular endothelial growth factor-A”. Blood 105 (2005): 1405-1407.
  24. Andrae J., et al. “Role of platelet-derived growth factors in physiology and medicine”. Genes and Development10 (2008): 1276-1312.
  25. Seo MS., et al. “Photoreceptor-specific expression of platelet-derived growth factor-B results in traction retinal detachment”. The American Journal of Pathology3 (2000): 995-1005.
  26. Zehetner C., et al. “Systemic upregulation of PDGF-B in patients with neovascular AMD”. Investigative Ophthalmology and Visual Science 1 (2014): 337-344.
  27. Jo N., et al. “Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization”. The American Journal of Pathology6 (2006): 2036-2053.
  28. Lin B., et al. “Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1”. Gene 654 (2018): 77-86.
  29. Tsioumpekou M., et al. “Specific targeting of PDGFRβ in the stroma inhibits growth and angiogenesis in tumors with high PDGF-BB expression”. Theranostics 3 (2020): 1122.
  30. Li H., et al. “Role of TGF-Beta1/SMAD2/3 Pathway in Retinal Outer Deep Vascular Plexus and Photoreceptor Damage in Rat 50/10 Oxygen-Induced Retinopathy”. BioMed Research International 2019 (2019).
  31. Nagineni CN., et al. “Transforming growth factor‐β induces expression of vascular endothelial growth factor in human retinal pigment epithelial cells: Involvement of mitogen‐activated protein kinases”. Journal of Cellular Physiology3 (2003): 453-462.
  32. Sood BG., et al. “Perinatal systemic inflammatory response syndrome and retinopathy of prematurity”. Pediatric Research4 (2010): 394-400.
  33. Saika S. “TGF β pathobiology in the eye”. Laboratory Investigation2 (2006): 106-115.
  34. Cerezo AB., et al. “Anti-VEGF signalling mechanism in HUVECs by melatonin, serotonin, hydroxytyrosol and other bioactive compounds”. Nutrients10 (2019): 2421.
  35. Xu Y., et al. “Melatonin attenuated retinal neovascularization and neuroglial dysfunction by inhibition of HIF‐1α‐VEGF pathway in oxygen‐induced retinopathy mice”. Journal of Pineal Research4 (2018): e12473.
  36. Sarlos S., et al. “Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF, and angiopoietin”. American Journal of Pathology3 (2003): 879-887.
  37. Tamarat R., et al. “Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor- and inflammation-related pathways”. Laboratory Investigation 82 (2002): 747-756.


Citation: Osipova NA., et al. “Studying the Pathogenesis of Retinopathy of Prematurity - From Theory to Practice”.Acta Scientific Medical Sciences 5.11 (2021): 128-135.


Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.403

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is April 30th, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue".
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US